Clinical Trials Arena on MSN

enGene’s NMIBC gene therapy touts 63% complete response in pivotal trial

Gene anticipates filing a biologics licence application (BLA) for detalimogene voraplasmid to the FDA in H2 2026.

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

BOSTON & MONTREAL, November 11, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non ...
Pharm Exec

FDA Files CRL for Supplemental Biologics License Application for Darzalex Faspro

The FDA's CRL for Darzalex Faspro was due to facility inspection issues, not safety or efficacy concerns. Darzalex Faspro's supply and availability remain unaffected, and no new clinical studies were ...
TipRanks on MSN

enGene reports detalimogene shows complete response rate of 62% at 6 months

Holdings reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene ...
Business Insider

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against ...